1-2 of 2
Fangrong Yan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas

Available to Purchase
Xiaofan Lu, Yann Vano, Alexandra Helleux, Xiaoping Su, Véronique Lindner, Guillaume Davidson, Roger Mouawad, Jean-Philippe Spano, Morgan Rouprêt, Reza Elaidi, Eva Compérat, Virginie Verkarre, Chengming Sun, Christine Chevreau, Mostefa Bennamoun, Hervé Lang, Thibault Tricard, Wenxuan Cheng, Li Xu, Irwin Davidson, Fangrong Yan, Wolf Herman Fridman, Catherine Sautes-Fridman, Stéphane Oudard, Gabriel G. Malouf
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1279–1291.
https://doi.org/10.1158/1078-0432.CCR-22-2133
Published: 03 April 2023
View articletitled, An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
Open the PDF for An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas in another window
Includes: Supplementary data
Journal Articles

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

Free
Fangrong Yan, Sumithra J. Mandrekar, Ying Yuan
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 3994–4003.
https://doi.org/10.1158/1078-0432.CCR-17-0220
Published: 01 August 2017
View articletitled, Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
Open the PDF for Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials in another window
Includes: Supplementary data